Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Schedule 1 - Original Invest

6 Oct 2006 16:28

AIM06 October 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME: ORIGINAL INVESTMENTS PLC (TO BE RENAMED VIALOGY PLC ON ADMISSION) COMPANY ADDRESS: ASHCOME COURTWOOLSACK WAYGODALMINGSURREY COMPANY POSTCODE: GU7 1LQ COUNTRY OF INCORPORATION: UK COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES: ViaLogy was founded in 1999 by a group of senior scientists and managers in supercomputing and ultra-computingtechnologies at the Caltech/NASA Jet Propulsion Laboratory (JPL) in Pasadena, California. Leveraging their priorexpertise and work at JPL in remote sensing and signal processing, ViaLogy scientists developed a technology toseparate the background 'noise' that envelops weak signals called Quantum Resonance Interferometry (QRI), which has thepotential to be adapted to a wide range of measurement, instrumentation and other applications. The initial test results on QRI, undertaken in the microarray industry, indicated that the technology was able todetect and discriminate signals with an intensity 1,000 times lower than RMS (root mean square) background noise. Thetechnology was the subject of further development work undertaken in the mass spectrometry industry. Other developmentactivities were carried out in the areas of sensor data processing and transference. The board and management team of ViaLogy consider that the technology is sufficiently advanced to be of considerablebenefit in a number of industrial areas and a planned programme of commercialisation has commenced. Discussions at bothdevelopment and commercial levels are being held with a number of international companies and national authorities toverify the suitability of incorporating the ViaLogy technology into existing and/or new products. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which itseeks admission and the number and type to be held as treasury shares): 403,256,437 ORDINARY SHARES OF 1P EACH CAPITAL TO BE RAISED ON ADMISSION: NIL FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS: DIRECTORS: JAMES DERRICK SLATER, CHAIRMAN (TO RESIGN ON ADMISSION) TERENCE BOND, MANAGING DIRECTOR AND DEPUTY CHAIRMAN (TO BECOME EXECUTIVE CHAIRMAN ON ADMISSION) DR RICHARD PETER DIXEY, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) JULIAN GEORGE VIGGARS, NON EXECUTIVE DIRECTOR (TO RESIGN ON ADMISSION) PROPOSED DIRECTORS: MICHAEL WOODS KELLY, PROPOSED CHIEF EXECUTIVE OFFICER DR. SANDEEP GULATI, PROPOSED CHIEF TECHNICAL OFFICER GEORGE REHM, PROPOSED NON-EXECUTIVE DIRECTOR DR. ROBERT WILLIAM DEAN, PROPOSED NON-EXECUTIVE DIRECTOR PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION: Existing Following AdmissionDirector Number of Percentage of Number of Percentage of Ordinary Shares issued ordinary Ordinary Shares issued ordinary share capital (%) share capital (%) James Derrick Slater 26,485,000 8.5 26,485,000 6.6Terence Bond 13,925,000 4.5 13,925,000 3.5Christopher Slater 12,585,000 4.0 12,585,000 3.1Atlas Capital S.A. 17,700,000 5.7 17,700,000 4.4Dr. John Broome 12,500,000 5.3 13,316,542 3.3Aeris Holdings AG Nil Nil 60,883,923 15.1 NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: NONE ANTICIPATED ACCOUNTING REFERENCE DATE: 31 MARCH EXPECTED ADMISSION DATE: 30 OCTOBER 2006 NAME AND ADDRESS OF NOMINATED ADVISER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL NAME AND ADDRESS OF BROKER: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THISWILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: SEYMOUR PIERCE LIMITEDBUCKLERSBURY HOUSE3 QUEEN VICTORIA STREETLONDON EC4N 8EL THE ADMISSION DOCUMENT CONTAINS FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES. DATE OF NOTIFICATION: 6 OCTOBER 2006 NEW/ UPDATE (see note): NEW This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.